Role of serum Nogo-B as a biomarker for diagnosis of chronic liver diseases and its severity

Abstract Background Nogo-B is one of the members of the reticulon family. Nogo-B influences the proliferation of the hepatic stellate cells inducing liver fibrotic changes. We aimed at measuring the serum levels of Nogo-B in patients with chronic liver disease (CLD) with different etiologies. Ninety subjects were included, 18 of them were normal healthy individuals and 72 had liver disease (fibrosis/cirrhosis) with different etiologies: post-hepatitis C infection, post-hepatitis B infection, NASH, and autoimmune hepatitis. Serum Nogo-B was assessed using ELISA. Patients were subdivided according to the Child-Pugh score into 3 groups: group 1—Child A (24 patients); group 2—Child B (24 patients); and group 3—Child C (24 patients). Results Serum Nogo-B levels were found to be significantly higher in patients (1477.92 ± 1113.50) when compared with healthy control (301.28 ± 180.87) (p < 0.001). There was a statistically significant difference in serum Nogo-B level between the three sub-groups of patients (p < 0.001). A positive correlation was found between serum Nogo-B and MELD score (r = 0.46, p-value < 0.001). However, there was no correlation found between Nogo-B and FIB-4 index or APRI score. There was a significant positive correlation between serum Nogo-B level and coagulation profile and serum bilirubin. An inverse correlation was found between serum Nogo-B with serum albumin. A ROC curve was done to examine the validity of Nogo-B in the diagnosis of liver cirrhosis, and the area under the curve was found to be 0.979, a cutoff value of 600 with a sensitivity of 97.2% and a specificity of 94.4% (p-value < 0.001). Conclusion Nogo-B had a high value in the identification of patients with any severity of CLD. There is a highly significant correlation between Nogo-B and the synthetic function of the liver; it could be used as a measure of hepatic functional reserve.

Download Full-text

Genetic predictors of spontaneous viral elimination or chronic liver disease in hepatitis C infection

Gastroenterology ◽

10.1016/s0016-5085(01)80033-0 ◽

2001 ◽

Vol 120 (5) ◽

pp. A7-A7

Author(s):

S ROSS ◽

S MASCHERETTI ◽

H HINRICHSEN ◽

P BUGGISCH ◽

U FOELSCH ◽

...

Keyword(s):

Liver Disease ◽

Hepatitis C ◽

Chronic Liver Disease ◽

Chronic Liver ◽

Hepatitis C Infection ◽

Genetic Predictors

Download Full-text

Genetic polymorphisms as predictors of chronic liver disease in hepatitis C infection

Journal of Hepatology ◽

10.1016/s0168-8278(01)80410-4 ◽

2001 ◽

Vol 34 (0) ◽

pp. 114

Author(s):

H Hinrichsen

Keyword(s):

Liver Disease ◽

Hepatitis C ◽

Chronic Liver Disease ◽

Genetic Polymorphisms ◽

Chronic Liver ◽

Hepatitis C Infection

Download Full-text

COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study

Gut ◽

10.1136/gutjnl-2021-324879 ◽

2021 ◽

pp. gutjnl-2021-324879

Author(s):

Luca Saverio Belli ◽

Christophe Duvoux ◽

Paolo Angelo Cortesi ◽

Rita Facchetti ◽

Speranta Iacob ◽

...

Keyword(s):

Liver Disease ◽

Respiratory Failure ◽

Meld Score ◽

Decompensated Cirrhosis ◽

Cox Regression Analysis ◽

Post Transplant ◽

End Stage Liver Disease ◽

Significant Difference ◽

End Stage ◽

The Impact

ObjectiveExplore the impact of COVID-19 on patients on the waiting list for liver transplantation (LT) and on their post-LT course.DesignData from consecutive adult LT candidates with COVID-19 were collected across Europe in a dedicated registry and were analysed.ResultsFrom 21 February to 20 November 2020, 136 adult cases with laboratory-confirmed SARS-CoV-2 infection from 33 centres in 11 European countries were collected, with 113 having COVID-19. Thirty-seven (37/113, 32.7%) patients died after a median of 18 (10–30) days, with respiratory failure being the major cause (33/37, 89.2%). The 60-day mortality risk did not significantly change between first (35.3%, 95% CI 23.9% to 50.0%) and second (26.0%, 95% CI 16.2% to 40.2%) waves. Multivariable Cox regression analysis showed Laboratory Model for End-stage Liver Disease (Lab-MELD) score of ≥15 (Model for End-stage Liver Disease (MELD) score 15–19, HR 5.46, 95% CI 1.81 to 16.50; MELD score≥20, HR 5.24, 95% CI 1.77 to 15.55) and dyspnoea on presentation (HR 3.89, 95% CI 2.02 to 7.51) being the two negative independent factors for mortality. Twenty-six patients underwent an LT after a median time of 78.5 (IQR 44–102) days, and 25 (96%) were alive after a median follow-up of 118 days (IQR 31–170).ConclusionsIncreased mortality in LT candidates with COVID-19 (32.7%), reaching 45% in those with decompensated cirrhosis (DC) and Lab-MELD score of ≥15, was observed, with no significant difference between first and second waves of the pandemic. Respiratory failure was the major cause of death. The dismal prognosis of patients with DC supports the adoption of strict preventative measures and the urgent testing of vaccination efficacy in this population. Prior SARS-CoV-2 symptomatic infection did not affect early post-transplant survival (96%).

Download Full-text

THU0433 TREATMENT WITH PEGLOTICASE IMPROVES HEPATIC FIBROSIS ESTIMATED BY FIBROSIS-4 INDEX IN SUBJECTS WITH CHRONIC REFRACTORY GOUT

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.2360 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 454.1-454

Author(s):

N. Schlesinger ◽

A. Yeo ◽

P. Lipsky

Keyword(s):

Liver Disease ◽

Linear Regression ◽

Rank Order ◽

Linear Regression Analysis ◽

Area Under The Curve ◽

Serum Urate ◽

Complete Analysis ◽

Alcoholic Fatty Liver ◽

Significant Difference ◽

The Impact

Background:Hyperuricemia is associated with non-alcoholic fatty liver disease (NAFLD)1,2, but the relationship to fibrosis remains uncertain3. Moreover, it is not known whether lowering serum urate will affect the course of NAFLD. The availability of data from two randomized trials of pegloticase, a pegylated recombinant mammalian uricase, that profoundly decreases serum urate afforded the opportunity to test the hypothesis that lowering urate might improve NAFLD.Objectives:To determine whether treatment of chronic refractory gout patients with pegloticase was associated with improvement in NAFLD determined by Fibrosis 4 index (Fib4).Methods:Databases from patients with chronic refractory gout who participated in two randomized 6 month clinical trials (RCTs) of pegloticase were analyzed4. Sub-sets who had persistent urate lowering to levels <1 mg/dL in response to biweekly pegloticase (Responders, n=36) were compared to those who received placebo (n=43). Since liver biopsy information was not available on these subjects, we relied on Fib4, a validated non-invasive estimate of liver fibrosis in a variety of liver diseases5,6calculated from measurements of AST, ALT, platelet count and age (Age x AST/platelets x √ALT). A Fib4 value of 1.3 is an indication that further evaluation of liver disease is warranted.Results:At baseline, the mean Fib4 values were 1.40 ± 0.86 in pegloticase responders and 1.04 ± 0.53 in subjects receiving placebo. As shown in figure 1, subjects receiving placebo exhibited a change of 0.26 ± 0.41 in the Fib4 score over the six months of the RCTs compared with 0.13 ± 0.62 in the pegloticase responders (p=0.048; by linear regression). When only the subjects with a Fib4 value > 1.3 were considered, a significant difference in the change in the Fib4 values over the 6 months of the trial between pegloticase responders and those receiving placebo was also observed (-0.15 ± 0.67 vs 0.37 ± 0.42, p=0.004, by linear regression). The correlations between serum urate area under the curve (AUC) over the 6 months of the trial and the change in Fib4 value was rs=0.33, p=0.0.0004 (Spearman rank-order correlation coefficient). Finally, multiple linear regression analysis indicated serum urate AUC (as a surrogate measure for group) is the main contributor to the change in Fib4 (p=0.018 by linear regression).Conclusion:The data are consistent with the conclusion that persistent lowering of serum urate had a significant impact on Fib4 levels, implying a possible effect on the course of NAFLD. The results support a more complete analysis involving biopsy examination of the impact of urate on liver inflammation and fibrosis.References:[1]Yang C et al. PlosOne2017; 12:e0177249[2]Jaruvongvanich V et al. Eur J Gastroenterol Hepatol 2017; 29:1031[3]Jaruvongvanich V et al. Eur J Gastroenterol Hepatol 2017; 29:694[4]Sundy JS, et al. JAMA. 2011; 306 (7):711-20[5]Sterling RK et al. Hepatol 2006; 43:1317[6]Shah AG et al. Clin Gastroenterol Hepatol 2009;7:1104Disclosure of Interests: :Naomi Schlesinger Grant/research support from: Pfizer, Amgen, Consultant of: Novartis, Horizon Therapeutics, Selecta Biosciences, Olatec, IFM Therapeutics, Mallinckrodt Pharmaceuticals, Anthony Yeo Employee of: Horizon Therapeutics, Peter Lipsky Consultant of: Horizon Therapeutics

Download Full-text

Chronic liver disease not a significant comorbid condition for COVID-19

Scientific Reports ◽

10.1038/s41598-021-91238-8 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Jiahao Lin ◽

Bingting Bao ◽

Nigar Anjuman Khurram ◽

Kasey Halsey ◽

Ji Whae Choi ◽

...

Keyword(s):

Liver Disease ◽

Liver Injury ◽

Chronic Liver Disease ◽

The United States ◽

Postmortem Examination ◽

Chronic Liver ◽

Critical Groups ◽

Comorbid Condition ◽

Central Vein ◽

Significant Difference

AbstractTo explore the role of chronic liver disease (CLD) in COVID-19. A total of 1439 consecutively hospitalized patients with COVID-19 from one large medical center in the United States from March 16, 2020 to April 23, 2020 were retrospectively identified. Clinical characteristics and outcomes were compared between patients with and without CLD. Postmortem examination of liver in 8 critically ill COVID-19 patients was performed. There was no significant difference in the incidence of CLD between critical and non-critical groups (4.1% vs 2.9%, p = 0.259), or COVID-19 related liver injury between patients with and without CLD (65.7% vs 49.7%, p = 0.065). Postmortem examination of liver demonstrated mild liver injury associated central vein outflow obstruction and minimal to moderate portal lymphocytic infiltrate without evidence of CLD. Patients with CLD were not associated with a higher risk of liver injury or critical/fatal outcomes. CLD was not a significant comorbid condition for COVID-19.

Download Full-text

Procollagen peptide serum levels in chronic liver disease: Comparison of antibody — And FAB — Radioimmunoassays for assessment of liver fibrosis

Journal of Hepatology ◽

10.1016/s0168-8278(85)80737-6 ◽

1985 ◽

Vol 1 ◽

pp. S351

Keyword(s):

Liver Disease ◽

Liver Fibrosis ◽

Chronic Liver Disease ◽

Serum Levels ◽

Chronic Liver

Download Full-text

TOLAK UKUR FUNGSI HATI BERDASARKAN DERAJAT FIBROSIS PENYAKIT HATI KRONIS (Liver Function Parameters based on Degree of Liver Fibrosis in Chronic Liver Disease)

INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY ◽

10.24293/ijcpml.v21i1.1260 ◽

2018 ◽

Vol 21 (1) ◽

pp. 57

Author(s):

Rahmafitria Rahmafitria ◽

Mutmainnah Mutmainnah ◽

Ibrahim Abdul Samad

Keyword(s):

Liver Disease ◽

Liver Fibrosis ◽

Liver Function ◽

Chronic Liver Disease ◽

Total Bilirubin ◽

Chronic Liver ◽

Low Degree ◽

Significant Difference ◽

The Mean ◽

High Degree

Evaluating the degree of liver fibrosis degree is invasive as well as uncomfortable, therefore, non invasive examinations such as liverfunction tests and elastography (Fibro Scan) as a predictor‘s device of liver fibrosis degree are necessary. The aim of this study was toknow the differences of liver function parameters based on the fibrosis degree in patients with chronic liver disease. This study was a crosssectional design using data from chronic liver disease patients treated at the Dr. Wahidin Sudirohusodo Hospital. The elasticity of the liverwas measured using a fibro scan device during June 2010–July 2011. The analysis was carried out by ANOVA test on various parametersof liver function particularly on the fibrosis degree in chronic liver disease. In this study PT, albumin, total bilirubin and platelet countshowed a significant difference of 0.019, 0.009, 0.017 and 0.000 respectively. The mean values of PT and total bilirubin were significantlyhigher in the high degree of fibrosis compared to those with medium and low degree of fibrosis in the chronic liver disease patients. Basedon this study, the mean albumin levels and platelet count were significantly lower in the high degree of fibrosis compared with the mediumand low degree of fibrosis, however, no significant differences in AST, ALT, APTT and GGT were found.

Download Full-text

Combination of FIB-4 with ultrasound surface nodularity or elastography as predictors of histologic advanced liver fibrosis in chronic liver disease

Scientific Reports ◽

10.1038/s41598-021-98776-1 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Maryam Moini ◽

Fernanda Onofrio ◽

Bettina E. Hansen ◽

Oyedele Adeyi ◽

Korosh Khalili ◽

...

Keyword(s):

Liver Disease ◽

Chronic Liver Disease ◽

Transient Elastography ◽

Area Under The Curve ◽

High Specificity ◽

Serum Markers ◽

Chronic Liver ◽

Alcoholic Fatty Liver ◽

Advanced Liver Fibrosis ◽

Independent Association

AbstractReliable and available non-invasive methods for hepatic fibrosis assessment are important in chronic liver disease (CLD). Our aim was to compare stepwise algorithms combining standard ultrasound with serum markers and transient elastography (TE) for detecting advanced fibrosis (F3-4) and cirrhosis. Retrospective single center study between 2012 and 2018 of CLD patients with biopsy, TE, blood tests, and liver ultrasound parameters of surface nodularity (SN), lobar redistribution, and hepatic vein nodularity. Our cohort included 157 patients (51.6% males), mean age 47.6 years, predominantly non-alcoholic fatty liver disease and viral hepatitis (61%), with F3-4 prevalence of 60.5%. Area under the curve for F3-4 was 0.89 for TE ≥ 9.6 kPa and 0.80 for FIB-4 > 3.25. In multivariate modeling, TE ≥ 9.6 kPa (OR 21.78) and SN (OR 3.81) had independent association with F3-4; SN (OR 5.89) and TE ≥ 10.2 kPa (OR 15.73) were independently associated with cirrhosis. Two stepwise approaches included FIB-4 followed by SN or TE; sensitivity and specificity of stepwise SN were 0.65 and 1.00, and 0.89 and 0.33 for TE ≥ 9.6 kPa, respectively. Ultrasound SN and TE were independently predictive of F3-4 and cirrhosis in our cohort. FIB-4 followed by SN had high specificity for F3-4.

Download Full-text

Serum levels of CXCL-8, IL-10, and TNF-alpha in ankylosing spondylitis patients

Biomedicine ◽

10.51248/.v41i3.775 ◽

2021 ◽

Vol 41 (3) ◽

Author(s):

Dhuha Karim

Keyword(s):

Disease Severity ◽

Functional Disability ◽

White Blood Cells ◽

Age Groups ◽

Area Under The Curve ◽

Serum Levels ◽

Hla B27 ◽

Diagnostic Significance ◽

Significant Difference ◽

Wbc Count

The mean age of AS patients was (35.0 ± 9.8) years.When the patients and control subjects were divided into different age groups (>40, 30-40, <30 years), the differences were not significantin terms of disease prevalence. The results also showed that the percentage of male patients is higher than that of females. There was no significant difference (P?0.05) between patients and controls in the distribution of males and females.Most of the patients had the disease for a period of 5 years or higher, with a disease severity of ? 2.1 and functional disability degree of I, II. The resultsshoweddifferent patterns of distribution for the three tested cytokines. A significant increase in the level of TNF-?, anon-significantincrease in the level of CXCL-8, and a significant decrease in the level of IL-10 were observed in the sera of patients with AS compared with the control.The patients also demonstrated significant decreases in the serum ALT and AST enzyme levels, hemoglobin (Hb) level, white blood cells (WBC) count, and erythrocyte sedimentation rate (ESR) (P?0.05).The percentage of HLA-B27-positive Iraqi patients was lower than that of the HLA-B27-negative patients. Some of these patterns were also exposed to changes related to some determinants in patients, which included age, sex, disease duration, disease severity, functional disability, and HLA-B27 positivity,along with association with clinical subtypes of AS.The area under the curve was determined for the parameters of ESR, IL-10, TNF-? and CXCL-8.The most significant factor was found to beESR, followed by IL-10, and then TNF-?, with the presence of significant differences, while there was no diagnostic significance for CXCL-8 ,which showed no significant difference (p?0.05).

Download Full-text